Artelo Biosciences, Inc.
ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal foā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.60
Price+3.23%
$0.05
1Y
Price
Market Cap
$3.230m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$12.491m
-27.1%
1y CAGR-8.3%
3y CAGR-15.1%
5y CAGREPS
-$17.30
-467.2%
1y CAGR-151.4%
3y CAGR-103.2%
5y CAGRBook Value
-$633k
$4.267m
Assets$4.900m
Liabilities$954k
DebtDebt to Assets
22.4%
-0.1x
Debt to EBITDAFree Cash Flow
-$8.176m
+2.1%
1y CAGR-0.7%
3y CAGR-8.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company